Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Buy” by Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned an average rating of “Buy” from the ten analysts that are currently covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $46.43.

Several research firms have recently commented on DNTH. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Oppenheimer raised their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC lifted its position in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares in the last quarter. SG Americas Securities LLC boosted its position in Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock valued at $242,000 after buying an additional 4,506 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Dianthus Therapeutics in the 2nd quarter valued at approximately $236,000. Fred Alger Management LLC increased its position in shares of Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after acquiring an additional 3,316 shares during the period. Finally, Point72 DIFC Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter worth about $334,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Up 4.1 %

DNTH opened at $20.00 on Tuesday. The firm’s fifty day simple moving average is $23.47 and its two-hundred day simple moving average is $26.36. Dianthus Therapeutics has a 52-week low of $10.65 and a 52-week high of $33.77. The company has a market cap of $592 million, a price-to-earnings ratio of -8.00 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, research analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.